| References: |
BMN-673 is an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. PARP inhibitor BMN-673 selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks. BMN-673 has been proven to be highly active in mouse models of human cancer and also appears to be more selectively cytotoxic with a longer half-life and better bioavailability as compared to other compounds in development. Check For active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).
For the detailed information about the solubility of BMN-673 in water, the solubility of BMN-673 in DMSO, the solubility of BMN-673 in PBS buffer, the animal experiment（test） of BMN-673,the in vivo,in vitro and clinical trial test of BMN-673,the cell experiment（test） of BMN-673,the IC50, EC50 and Affinity of BMN-673, please contact DC Chemicals. |
